Upfront adjuvant exemestane shows benefit over tamoxifen

Owen, Olwen Glynn
January 2009
British Journal of Hospital Medicine (17508460);Jan2009, Vol. 70 Issue 1, p10
Academic Journal
The article features the research conducted by the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) regarding the efficacy of adjuvant exemestane in treating breast cancer in women in Great Britain. Results show that patients showing early stages of breast cancer, treated with adjuvant exemestane therapy after surgery, chemotherapy or radiotherapy, experienced fewer breast cancer recurrences and occurrence of metastases than those treated with 2-3 years of tamoxifen before receiving exemestane.


Related Articles

  • Bisphenol A at Low Nanomolar Doses Confers Chemoresistance in Estrogen Receptor-α--Positive and --Negative Breast Cancer Cells. LaPensee, Elizabeth W.; Tuttle, Traci R.; Fox, Sejal R.; Ben-Jonathan, Nira // Environmental Health Perspectives;Feb2009, Vol. 117 Issue 2, p175 

    BACKGROUND: Resistance to chemotherapy is a major problem facing breast cancer patients, and identifying potential contributors to chemoresistance is a critical area of research. Bisphenol A (BPA) has long been suspected to promote carcinogenesis, but the high doses of BPA used in many studies...

  • OncotypeDX-guided treatment of breast cancer cost effective.  // PharmacoEconomics & Outcomes News;6/2/2007, Issue 529, p12 

    The article discusses research being done on the OncotypeDX-guided treatment of breast cancer. It references a study by G. H. Lyman et al published in the March 15, 2007 issue of "Cancer." According to U.S. researchers, treatment decisions based on the OncotypeDX recurrence score are associated...

  • More Evidence That Race Affects Breast Cancer Survival.  // RN;Apr2007, Vol. 70 Issue 4, p16 

    The article focuses on the findings of research stating that race plays a bigger role in the biology of breast tumors and response to treatment. The tumor characteristics and outcomes of 2,140 women with breast cancer treated with doxorubicin chemotherapy before or after mastectomy in two...

  • Many women not concordant with breast cancer drugs.  // Nursing Standard;4/29/2009, Vol. 23 Issue 34, p16 

    The article discusses the compliance of women patients taking drug therapies for breast cancer and a German study on compliance for women taking tamoxifen and aromatase inhibitors. Compliance in patients taking tamoxifen is reported as low. The study found that all women taking the medicines...

  • Treatment - Neoadjuvant and Adjuvant Therapy.  // Current Medical Literature: Breast Cancer;2010, Vol. 22 Issue 3, p101 

    The article discusses research on breast cancer treatment with neoadjuvant and adjuvant therapy. A study by M. D. Holmes et al published in the "Journal of Clinical Oncology" focused on the use of aspirin in breast cancer treatment among women. A study by T. Byrski et al published in the...

  • Drug Eases Chemo Side Effect.  // Saturday Evening Post;Jan/Feb2006, Vol. 278 Issue 1, p46 

    This article discusses research being done on the impact of prescription antiseizure drug Neurontin or gabapentin on women receiving chemotherapy for breast cancer who suffered from hot flashes. After eight weeks of treatment, the research team compared the fall in hot flashes among the group...

  • Protein found to thwart chemotherapy in breast cancer.  // Journal of Business (10756124);3/22/2007, Vol. 22 Issue 7, pA18 

    The article discusses a study which examines new biological markers that will help indicate whether a woman's breast cancer will respond to prescribed chemotherapy drugs. According to research, breast-cancer tumors with high levels of the protein are protected from a common chemotherapy regimen...

  • New Research On Breast Cancer Among Latinas.  // Hispanic;Jan/Feb2003, Vol. 16 Issue 1/2, p12 

    Presents statistics on breast cancer research among Hispanic women, as of February 2003. Percentage of Hispanic women who are afflicted with breast cancer every year.

  • New Hopes, Longer Life. Kaelin, Carolyn M.; Fuller Jr., Arlan F.; Coltrera, Francesca // Newsweek (Atlantic Edition);5/8/2006 (Atlantic Edition), Vol. 147 Issue 19, p47 

    The article focuses on research into the genetic makeup that causes breast and ovarian cancers in women. Targeted drugs such as Herceptin and aromatase inhibitors are improving women's cancer treatment, but gene research has been slow and difficult. Surgery and intraperitoneal treatments are...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics